Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in <i>BRCA1</i> and/or <i>BRCA2</i> in the PROfound Trial.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 37963304.
- Also identified by DOI 10.1200/JCO.23.00339.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Olaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial.
Medical subject headings
- Prostatic Neoplasms, Castration-Resistant